The Word document is ready. Here is the complete article:
Monsanto Technology LLC & Ors. v. Nuziveedu Seeds Ltd. & Ors.
Can a Genetically Modified Seed Be Patented? The Supreme Court's Answer on Section 3(j), Summary Adjudication, and the Limits of Appellate Courts
A Supreme Court of India Analysis — Decided January 8, 2019
Introduction
Few intellectual property disputes in modern Indian legal history have generated as much public, commercial, and legal interest as the battle between Monsanto Technology LLC — a global agro-biotechnology giant — and Nuziveedu Seeds Limited, one of India's leading seed companies. The case, decided by the Supreme Court of India on January 8, 2019, sits at a remarkable crossroads: it touches on the patentability of genetically modified plant technology, the rights of Indian farmers, the relationship between two major laws — the Patents Act, 1970 and the Protection of Plant Varieties and Farmers' Rights Act, 2001 (PPVFR Act) — and the fundamental question of how far an appellate court can go in deciding complex technical questions without a proper trial. The Supreme Court's judgment, authored by Justice Navin Sinha (with Justice Rohinton Fali Nariman concurring), is ultimately not a verdict on whether Monsanto's patent is valid or invalid. It is, rather, a firm and principled statement that questions of such profound complexity — involving biotechnology, genetic science, and competing statutory regimes — cannot be decided in a hurried or summary fashion at the stage of an interim injunction, without evidence, without expert witnesses, and without a full trial. In doing so, the Court corrected a significant overreach by the Division Bench of the Delhi High Court and restored procedural sanity to a dispute that had enormous implications for Indian agriculture and intellectual property law.
Factual and Procedural Background
The story begins with a sub-licence agreement dated February 21, 2004, between Monsanto Technology LLC (along with its Indian affiliate Mahyco Monsanto Biotech India Limited) as the licensor, and Nuziveedu Seeds Limited along with associated seed companies as the licensees. The agreement was entered for an initial period of ten years and authorised Nuziveedu to develop what are called Genetically Modified Hybrid Cotton Planting Seeds using Monsanto's proprietary technology. In plain terms, Nuziveedu was permitted to use Monsanto's special gene technology — the so-called Bt. cotton technology, marketed under the trademark 'BOLGARD' and 'BOLGARD II' — to develop cotton seeds that are resistant to certain destructive insects, particularly Bollworms. In exchange for this licence, Nuziveedu was required to pay a licence fee or trait value to Monsanto for every unit of seed sold incorporating Monsanto's technology.
The arrangement worked for several years, but tensions arose when State governments introduced a price control regime that significantly capped the amount that could be charged for Bt. cotton seeds, including the trait value component payable to Monsanto. Nuziveedu took the position that the payments had to be in accordance with the statutory price caps fixed by the government. Monsanto disagreed. Unable to resolve the dispute, Monsanto terminated the sub-licence agreement on November 14, 2015, declaring that Nuziveedu no longer had any authorisation to use its patented technology.
Monsanto thereafter instituted Civil Suit (Comm) No. 132 of 2016 before the Delhi High Court, seeking a permanent injunction against Nuziveedu from using the trademarks 'BOLGARD' and 'BOLGARD II', restraining Nuziveedu from selling seeds bearing the patented technology, and seeking rendition of accounts. The suit was founded on Monsanto's registered patent No. 214436. Along with the main suit, Monsanto also filed an application under Order 39, Rules 1 and 2 of the Code of Civil Procedure, 1908, seeking an interim injunction.
Nuziveedu defended itself vigorously. It contended that its activities were protected under the PPVFR Act, 2001, and that Monsanto's patent fell within the exclusion under Section 3(j) of the Patents Act, 1970, which prohibits patents for plants and animals in whole or any part thereof, essentially biological processes for production or propagation of plants and animals, and seeds. Nuziveedu also filed counter claim No. 51 of 2016 seeking revocation of Monsanto's patent under Section 64 of the Patents Act on the ground that it violated Section 3(j). A second counter claim No. 50 of 2016 challenging the termination of the sub-licence agreement was subsequently withdrawn.
The learned Single Judge, on March 28, 2017, passed a measured order on the interim injunction. Recognising that the issues necessarily required formal proof and expert opinion, the Single Judge did not go into the validity of the patent. He directed that during the pendency of the suit, both parties shall remain bound by their obligations under the sub-licence agreement, with the licence fee governed by the laws in force — meaning the statutory price regime. The Single Judge only issued notice on counter claim No. 51 of 2016 without adjudicating it.
Both sides preferred appeals before the Division Bench of the Delhi High Court. The Division Bench went far beyond the question of interim injunction. It examined the counter claim and upheld Nuziveedu's contention that the patent was excluded under Section 3(j). It held that the Patents Act and the PPVFR Act were not complementary but mutually exclusive for all processes and products falling within Section 3(j). Consequently, the counter claim succeeded and the suit was partially dismissed to the extent of injunctive relief based on the patent, though permitted to continue for damages. Monsanto was directed to continue its obligations under the sub-licence agreement. Aggrieved, Monsanto approached the Supreme Court.
The Dispute
The dispute before the Supreme Court had several layers. At the surface level, it was about whether the sub-licence agreement had been validly terminated and what injunctive relief was appropriate during the pendency of the suit. At a deeper level, it raised profound questions about the patentability of biotechnology inventions in India — specifically, whether a genetically engineered Nucleic Acid Sequence (NAS), a specially designed gene construct that imparts insect resistance to a cotton plant, could be the subject of a valid patent, or whether it fell within the exclusion under Section 3(j) of the Patents Act, 1970.
Monsanto's patent No. 214436 contained claims 1 to 24 relating to processes of inserting genetic material into plant cells, and claims 25 to 27 relating to the NAS as a chemical product. Monsanto's position was that the NAS was a man-made DNA construct that did not exist in nature, was not a plant or part of a plant, and was therefore patentable. The NAS comprised three components: a promoter, a man-made gene for the production of Cry2Ab 5-endotoxin (a protein toxic to insects), and a transit peptide. Monsanto maintained that a separate patent No. 232681 covered the 'event' of positioning the NAS within the plant genome — a different invention not the subject of the present suit. It also argued, relying on scientific literature by Guoyou et al. titled "Marker-Assisted Recurrent Backcrossing in Cultivar Development," that a NAS gene once inserted into a plant was removable and did not become a permanent part of the plant genome.
Nuziveedu and interveners took the opposite view. They argued that the NAS gene, once inserted, exists in every cell of the transformed plant, is inherited by all future generations perpetually, and cannot be meaningfully separated from the plant. Since the NAS acquires practical utility only inside a plant — where it is expressed through biological processes of transcription, translation, and replication — it effectively becomes part of a plant and falls within Section 3(j). Nuziveedu also argued that patent rights cannot be used to control the use of seeds in farmers' hands, whose rights are specifically protected under Sections 30 and 39 of the PPVFR Act. Interveners also raised the point that the Biodiversity Act required prior permission from the National Bio Diversity Authority for commercial use of biological resources, which the appellants had not obtained.
The critical procedural question — which became the central point of the Supreme Court's decision — was whether the Division Bench was right in deciding all these deeply complex scientific and legal questions summarily, at the interlocutory stage, without evidence, without expert witnesses, and without a proper trial.
Reasoning and Analysis of the Court
Justice Navin Sinha, writing for the Bench, took a decisive but restrained approach. The Court acknowledged that enormously elaborate submissions had been made by distinguished senior counsel on all sides — including Dr. Abhishek Manu Singhvi, Shri Kapil Sibal, Shri Neeraj Kaul, Shri K.V. Vishwanathan, Shri Arvind P. Datar, Shri Jayant Bhushan, Shri Krishnan Venugopal, Shri Shyam Divan, Shri Sanjiv Sen, Shri Prashant Bhushan, and Ms. Anandita Mitra — covering the Patents Act, the PPVFR Act, India's obligations under the WTO, GATT, the TRIPS Agreement, and the Patents Amendment Act, 2002 (which came into force on June 25, 2002). Despite the breadth of these submissions, the Court expressly declined to pronounce on any of those questions at that stage, leaving all questions of fact and law open for appropriate proceedings.
The heart of the Court's reasoning lay in its analysis of the procedural impropriety committed by the Division Bench. The Court pointed out a crucial fact: when both sides appealed before the Division Bench, the only legitimate question before it was whether the Single Judge's injunction order dated March 28, 2017 was correct or not. Monsanto itself, through Dr. Singhvi, conceded before the Supreme Court that the Single Judge's direction regarding the trait value being governed by the statutory price regime was acceptable. The Division Bench's legitimate task was therefore confined to examining the correctness of that injunction order.
The Division Bench, however, went much further. It examined and decided counter claim No. 51 of 2016 — the application for revocation of Monsanto's patent under Section 64 of the Patents Act — even though the counter claim had never been argued or adjudicated by the Single Judge. By summarily deciding the counter claim, the Division Bench effectively usurped the jurisdiction of the Single Judge who was the proper forum to try it after a full trial. The Supreme Court found this to be manifestly impermissible. The Court also rejected the Division Bench's reliance on alleged 'consent' of the parties to summary adjudication. The Court accepted Monsanto's argument that no holder of a valid registered patent would rationally consent to have its validity decided summarily — without evidence and at the interlocutory stage — risking losing the patent altogether without a fair trial on merits. The consent, if any, was only for the limited purpose of deciding whether the patent had been infringed, to determine the grant or refusal of interim injunction.
The Court reasoned that Section 64 of the Patents Act, which provides for revocation of a patent by counter claim in a suit, necessarily presupposes a valid and proper adjudication in accordance with law — with settlement of issues, examination of witnesses, discovery of documents, and expert evidence — and not a summary disposal based on textbooks and documents from the public domain, not even formally exhibited in the suit. The issues involved — chemical processes, biochemistry, biotechnology, microbiological processes, whether the nucleic acid sequence trait once inserted could be removed from a plant variety or not, and whether the patented DNA sequence was to be considered a plant or part of a plant under Section 3(j) — were all matters requiring expert testimony and a full evidentiary hearing at trial stage.
To reinforce this principle, the Court relied on the Supreme Court's earlier decision in Alka Gupta v. Narender Kumar Gupta, reported as MANU/SC/0793/2010 : (2010) 10 SCC 141. In that case, it was held that the Code of Civil Procedure, 1908 is an exhaustive compilation of the principles of natural justice as applicable to court proceedings, and its entire object is to ensure that adjudication is conducted with appropriate opportunities at appropriate stages. A civil suit has to be decided after framing issues and allowing parties to lead evidence — there are no shortcuts unless specifically provided by law. A court cannot dismiss a suit by deciding issues of fact merely on pleadings and documents without evidence tested by cross-examination. The Division Bench's approach in the present case squarely fell into this prohibited category: it had decided complicated questions of fact regarding patentability and Section 3(j) exclusion without any evidence, expert or otherwise.
Final Decision of the Court
The Supreme Court allowed the appeals filed by Monsanto and set aside the order of the Division Bench of the Delhi High Court. The order of the learned Single Judge dated March 28, 2017 was restored in its entirety. Civil Suit (Comm) No. 132 of 2016 was remanded to the learned Single Judge for disposal in accordance with law, meaning the full trial on all issues — including the validity of the patent and the counter claim for revocation under Section 64 — would proceed before the Single Judge on the basis of proper evidence. The Supreme Court expressed its expectation that the parties would cooperate and facilitate the Single Judge in the early disposal of the suit, given the importance of the questions involved. All appeals as well as intervention applications were disposed of accordingly.
Point of Law Settled
The judgment settles several important points of law. First, complex questions of patent validity — particularly those involving mixed questions of science and law such as the applicability of Section 3(j) of the Patents Act to biotechnological inventions — cannot be decided summarily at the interim injunction stage. They require a full trial with framing of issues, discovery, expert witnesses, and cross-examination. Second, a Division Bench hearing an appeal against an interim injunction order must confine itself to the correctness of that injunction and cannot usurp the jurisdiction of the trial court to summarily decide a counter claim for revocation never adjudicated below. Third, a counter claim for revocation of patent under Section 64 of the Patents Act is a serious proceeding requiring the same rigour as the main suit — it cannot be disposed of summarily without evidence. Fourth, the principle from Alka Gupta v. Narender Kumar Gupta, (2010) 10 SCC 141 is reinforced: a civil suit cannot be short-circuited by deciding questions of fact merely on pleadings and documents without a proper trial. Fifth, while the Court expressly declined to pronounce on the substantive questions — whether the NAS is patentable under the Patents Act, whether Section 3(j) excludes it, and whether the Patents Act and PPVFR Act are complementary or mutually exclusive — all these profound questions were kept alive for determination at the full trial. The case stands as a landmark on the procedural limits of summary adjudication in patent matters, while leaving the larger battleground of biotechnology patents and farmers' rights to be contested on evidence.
Case Details
Title: Monsanto Technology LLC and Ors. Vs. Nuziveedu Seeds Ltd. and Ors. Date of Order: January 8, 2019 Case Number: Civil Appeal Nos. 4616-4617 of 2018; Civil Appeal No. 188 of 2019 (arising out of SLP (C) No. 19411 of 2018); Civil Appeal Nos. 189-190 of 2019 (arising out of SLP (C) Nos. 16479-16480 of 2018); Civil Appeal Nos. 191-192 of 2019 (arising out of SLP (C) Nos. 19409-19410 of 2018) Neutral Citation: MANU/SC/0027/2019 Equivalent Citations: AIR 2019 SC 559; 2019 (1) SCALE 234 Name of Court: Supreme Court of India Coram: Hon'ble Mr. Justice Rohinton Fali Nariman and Hon'ble Mr. Justice Navin Sinha Judgment authored by: Justice Navin Sinha
Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Suggested SEO Titles:
- Monsanto v. Nuziveedu Seeds: Supreme Court on Patentability of Bt. Cotton Technology and Limits of Summary Adjudication — Section 3(j) Patents Act India
- Can Genetically Modified Seeds Be Patented in India? Supreme Court's Landmark Ruling in Monsanto v. Nuziveedu Seeds (2019)
- Section 3(j) Patents Act and GM Crop Patents: What the Supreme Court's 2019 Monsanto Decision Really Decided
- Monsanto Bt. Cotton Patent Dispute India: Supreme Court Restores Injunction and Remands for Full Trial — AIR 2019 SC 559 Analysed
- Patents Act vs. PPVFR Act in India: Supreme Court on Biotech Patents, Farmers' Rights, and the Limits of Appellate Courts in Monsanto v. Nuziveedu
- Summary Adjudication of Patent Validity at Interim Injunction Stage: Why the Division Bench Erred in Monsanto v. Nuziveedu Seeds — Supreme Court 2019
SEO Tags: Monsanto v Nuziveedu Seeds, Section 3(j) Patents Act India, Bt cotton patent India, GMO seeds patent India, genetically modified plant patent, PPVFR Act 2001, Protection of Plant Varieties and Farmers Rights Act, Patents Act 1970 India, patent revocation Section 64, interim injunction patent suit, Division Bench overreach patent, summary adjudication patent India, biotechnology patent India, nucleic acid sequence patent, BOLGARD patent, Cry2Ab endotoxin patent, Supreme Court patent 2019, MANU SC 0027 2019, AIR 2019 SC 559, Alka Gupta v Narender Kumar Gupta 2010 10 SCC 141, patent validity trial India, TRIPS India patent, WTO patent obligations India, farmers rights seeds India, Section 48 Patents Act, sub-licence agreement patent India, trait value Bt cotton, Mahyco Monsanto Biotech, Justice Navin Sinha patent, Justice Rohinton Fali Nariman, IP litigation India, patent infringement suit India, AdvocateAjayAmitabhSuman, IPAdjutor
Headnote:
Patents Act, 1970 — Section 3(j) (Exclusion from Patentability: Plants and Essentially Biological Processes) — Section 48 (Rights of Patentee) — Section 64 (Revocation of Patent by Counter Claim in Suit) — Protection of Plant Varieties and Farmers' Rights Act, 2001 — Code of Civil Procedure, 1908, Order 39 Rules 1 and 2 (Interim Injunction) — Sub-licence Agreement — Genetically Modified Bt. Cotton Seeds — Nucleic Acid Sequence (NAS) — Bolgard Technology — Summary Adjudication — Counter Claim — Full Trial — Expert Evidence.
The appellants held patent No. 214436 over a Nucleic Acid Sequence and related processes used to develop insect-resistant cotton plants under the trademark BOLGARD and BOLGARD II, and had entered into a sub-licence agreement dated February 21, 2004 with the respondent seed companies. The agreement was terminated on November 14, 2015 owing to disputes over licence fee/trait value under a statutory price control regime. The appellants filed a suit for injunction and the learned Single Judge, on March 28, 2017, ordered that both parties remain bound by their sub-licence obligations during the pendency of the suit, with the trait value governed by the prevailing law, without deciding counter claim No. 51 of 2016 for revocation of the patent. On appeal, the Division Bench went beyond the injunction question and decided the counter claim summarily, upholding patent exclusion under Section 3(j) of the Patents Act, revoking the patent without evidence or expert witnesses. The Supreme Court, setting aside the Division Bench order and restoring the Single Judge's order, held: (i) a Division Bench hearing an appeal against an interim injunction order must confine its examination to the correctness of that injunction and cannot usurp the jurisdiction of the Single Judge to summarily decide the counter claim for revocation; (ii) Section 64 of the Patents Act presupposes proper adjudication in accordance with law — with settlement of issues, examination of witnesses, discovery, and expert evidence — and not summary disposal based on documents from the public domain not even exhibited in the suit; (iii) the questions whether the NAS is a plant or part of a plant excluded under Section 3(j), whether the Patents Act and PPVFR Act are mutually exclusive, and all mixed questions of law and fact regarding patentability require full trial on evidence; (iv) a civil suit cannot be short-circuited by deciding issues of fact merely on pleadings and documents without trial, per Alka Gupta v. Narender Kumar Gupta, MANU/SC/0793/2010 : (2010) 10 SCC 141; (v) the nature of the injunctive relief granted by the Single Judge was in order and merited no interference during the pendency of the suit; (vi) all questions of law and fact regarding patentability, Section 3(j), and the relationship between the Patents Act and the PPVFR Act are left open for determination at the final hearing on evidence — Civil Appeal Nos. 4616-4617 of 2018 and connected appeals allowed, suit remanded to the Single Judge for disposal in accordance with law.
